80860-44-2

Basic information

• Product Name: 2-(((3aR,4R,6R,6aR)-6-(6-aMino-9H-purin-9-yl)-2,2-diMethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)Methyl)isoindoline-1,3-dione
• Synonyms: 2-(((3aS,4S,6S,6aS)-6-(6-amino-9H-purin-9-yl)-2,2-dimethyl-tetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methyl)isoindoline-1,3-dione;5'-Deoxy-2',3'-O-isopropylidene-5'-phthalimidoadenosine;5'-Deoxy-5'-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)-2',3'-O-(1-methylethylidene)adenosine;2-(((3AR,4R,6R,6aR)-6-(6-Amino-9H-purin-9-yl)-2,2-dimethyltetrahydrofuro-[3,4-d][1,3]dioxol-4-;2-(((3aR,4R,6R,6aR)-6-(6-aMino-9H-purin-9-yl)-2,2-diMethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)Methyl)isoindoline-1,3-dione;Adenosine, 5'-deoxy-5'-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)-2',3'-O-(1-Methylet hylidene)-;2-(3aR,4R,6R,6aR)-6-(6-aMino-9H-purin-9-yl-2,2-diMethyltetrahydrofuro[3.4-d][1.3]dioxol-4-yl Methyl isoindoline-1.3-dinoe;2-(((3AR,4R,6R,6aR)-6-(6-Amino-9H-purin-9-yl)-2,2-dimethyltetrahydrofuro-[3,4-d][1,3]dioxol-4-yl)
• CAS NO: 80860-44-2
• Molecular Formula: C₂₁H₂₀N₆O₅
• Molecular Weight: 436.4207
• Mol File: 80860-44-2.mol

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 2-(((3aR,4R,6R,6aR)-6-(6-aMino-9H-purin-9-yl)-2,2-diMethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)Methyl)isoindoline-1,3-dione(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(((3aR,4R,6R,6aR)-6-(6-aMino-9H-purin-9-yl)-2,2-diMethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)Methyl)isoindoline-1,3-dione(80860-44-2)
• EPA Substance Registry System: 2-(((3aR,4R,6R,6aR)-6-(6-aMino-9H-purin-9-yl)-2,2-diMethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)Methyl)isoindoline-1,3-dione(80860-44-2)

Safety Data

• Hazardous Substances Data: 80860-44-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2-(((3aR,4R,6R,6aR)-6-(6-aMino-9H-purin-9-yl)-2,2-diMethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)Methyl)isoindoline-1,3-dione is used as a potential pharmaceutical candidate for [specific application reason, if available] due to its unique structure and properties. Its complex molecular arrangement may offer novel therapeutic opportunities, and ongoing research could uncover its specific applications in medicine.

Upstream product

• 58-61-7 adenosine 
• 136918-14-4 phthalimide 
• 362-75-4 2',3'-isopropylidene adenosine 

Relevant articles and documents

Synthesis of an azide-bearing N-mustard analogue of S-adenosyl-L-methionine

The synthesis of an azide-bearing N-mustard S-adenosyl-L-methionine (SAM) analogue, 8-azido-5′-(diaminobutyric acid)-N-iodoethyl-5′- deoxyadenosine, has been accomplished in 10 steps from commercially available 2′,3′-isopropylidene adenosine. Critical to this success was executing C8 azidation prior to derivatizing the 5′-position of the ribose sugar and the late stage alkylation of the 5′ amino group with bromoethanol, which was necessitated by the reactivity of the aryl azide moiety. The azide-bearing N-mustard is envisioned as a useful biochemical tool by which to probe DNA and protein methylation patterns (Figure presented).

Efficient Synthesis of Azide-Bearing Cofactor Mimics

8-Azido-5′-aziridmo-5′-deoxyadenosine (6), a novel cofactor mimic, was synthesized in nine steps from commercially available 2′,3′-isopropylideneadenosine in ～4% overall yield. Crucial to this success was a very unorthodox phthalimide cleavage procedure, C8 azidation prior to aziridination and late stage alkylation of the 5′ amino group with iodoethanol necessitated by the high degree of lability endowed by the aryl azide moiety. Aziridine 6 is envisioned as a useful biochemical tool by which to probe DNA and protein methylation patterns.

Purine derivative and preparation method and application thereof

The invention discloses a purine derivative and a preparation method and application thereof, belongs to the technical field of medicines, and designs and synthesizes a series of purine derivatives and optical isomers, pharmaceutically acceptable salts, solvates or prodrugs of the purine derivatives. Experiments show that the compound has outstanding anti-cell proliferation activity and DOT1L enzyme inhibition effect, shows good tumor growth inhibition activity in a tumor transplantation tumor model, and has a good application prospect.

Purine compound containing bicyclic group, and preparation method thereof

The invention provides a purine compound containing a bicyclic group which is shown as a formula (I) and a formula (II) and a pharmaceutically acceptable salt, and a preparation method thereof. The compound is an inhibitor of histone methyltransferase DOT1L, and can be used for treating diseases caused by the abnormity of enzyme activity, such as tumor.

Cycloalkane analogues of sinefungin as EHMT1/2 inhibitors

A series of cycloalkyl substituted analogues of the natural product sinefungin lacking the amino-acid moiety was designed and synthesized. Two stereoisomers (6-R and 6-S) were separated and their bioactivities examined against EHMT1/2. Of which, compound 14d showed an inhibitory activity against EHMT1/2 (88.9%, IC50 = 21.8 μM for EHMT1 and 77.6%, IC50 = 39.6 μM for EHMT2, respectively) similar to that of sinefungin (100.0%, IC50 = 28.4 μM for EHMT1 and 79.5%, IC50 = 30.1 μM for EHMT2, respectively). Further studies against other methyltransferases such as PRMT1 showed no activity except that 12d displayed about 20% inhibition.

Synthesis and evaluation of adenosine containing 3-arylfuran-2(5H)-ones as tyrosyl-tRNA synthetase inhibitors

Tyrosyl-tRNA synthetase (TyrRS) is an aminoacyl-tRNA synthetase family protein that possesses an essential role in bacterial protein synthesis. The synthesis, structure-activity relationship, and evolution of a novel series of adenosine-containing 3-arylfuran-2(5H)-ones as TyrRS inhibitors are described. Advanced compound d3 from this series exhibited excellent affinity for TyrRS with IC50 of 0.61?±?0.04?μM. Bacterial growth inhibition assays demonstrated that d3 showed submicromolar antibacterial potency against Escherichia coli and Pseudomonas aeruginosa, and compared to the marketed antibiotics ciprofloxacin.

SULFANIDE ADENOSINE DERIVATIVES AND USES THEREOF

Described herein are sulfamide adenosine derivatives of Formula (I) or (II), and pharmaceutically acceptable salts, and pharmaceutical compositions thereof. Also provided are methods, uses, and kits involving the inventive compounds or pharmaceutical compositions for treating and/or preventing proliferative diseases (e.g., cancers, inflammatory diseases, and autoimmune diseases) or infectious diseases (e.g., bacterial infections, viral infections, fungal infections, and parasitic diseases) in a subject. The compounds and pharmaceutical compositions as described herein are thought to inhibit aminoacyl tRNA synthetase activity in a biological sample or subject to achieving the treatment of proliferative diseases or infectious diseases.

SELECTIVE INHIBITORS OF HISTONE METHYLTRANSFERASE DOT1L

Structure and mechanism based design was used to design potent ribose containing inhibitors of DOT1L with IC50 values as low as 38 nM. These ribose containing inhibitors exhibit only weak or no activities against four other representative histone lysine and arginine methyltransferases, G9a, SUV39H1, PRMT1 and CARM1.

Parallel solution-phase synthesis of an adenosine antibiotic analog library

A library of eighty one adenosine antibiotic analogs was prepared under the Pilot Scale Library Program of the NIH Roadmap initiative from 5′-amino-5′-deoxy-2′,3′-O-isopropylidene-adenosine 3. Diverse aldehyde, sulfonyl chloride and carboxylic acid reactant sets were condensed to 3, in solution-phase fashion, leading after acid-mediated hydrolysis to the targeted compounds in good yields and high purity. No marked antituberculosis or anticancer activity was noted on preliminary cellular testing, but these nucleoside analogs should be useful candidates for other types of biological activity.

MODULATORS OF HISTONE METHYLTRANSFERASE, AND METHODS OF USE THEREOF

Disclosed are compounds, pharmaceutical compositions containing the compounds, and the uses of the compounds and compositions as modulators of histone methyltransferases, and for treating diseases influenced by modulation of histone methyltransferase activity.